M&A Advisory in North Carolina
Charlotte's $7B+ in 2025 PE fundraising and a 2.25% corporate tax phasing to zero by 2030 make North Carolina the Southeast's most structurally advantaged M&A market — home to the #2 US banking center and one of three premier US biotech corridors.
North Carolina's M&A Economy
North Carolina entered 2025-2026 as arguably the most structurally attractive Southeast LMM market, named CNBC's "America's Top State for Business" in 2025 — the third time in four years. State GDP reached approximately $890B nominal, with real GDP growing 3.8% over Q3 2024-Q3 2025, more than double the 2.1% national rate. Four distinct forces drive deal flow: Research Triangle Park captured record biotech/life-science capex — Biogen's $2B RTP expansion, Novartis $771M, Fujifilm Biotechnologies' $3.2B Holly Springs facility, Amgen $1B, and Novo Nordisk $4.1B in Johnston County — fueling CDMO, CRO, and lab-services roll-ups; Charlotte as the #2 US banking center after NYC, home to Bank of America (~$2.8T assets) and Truist (~$500B), with SMBC announcing a $50.5M second US HQ in November 2025; legacy furniture and textiles in the Piedmont Triad consolidating into specialty manufacturing; and a fast-growing fintech corridor with 232,000 financial-services professionals statewide. The seller's tax environment is extraordinary: NC's flat corporate income tax of 2.25% in 2025 is the lowest among the 44 states levying a CIT, dropping to 2.0% in 2026 and phasing to 0% by 2030 under S.L. 2021-180. The personal income tax concurrently drops from 4.25% to 3.99% in 2026, and the franchise tax is capped at $500 on the first $1M of net worth. Charlotte-based PE firms Ridgemont ($3.975B Fund V), Pamlico ($1.75B), and Falfurrias ($1.35B) collectively raised over $7B in new capital in 2025 alone, creating fierce competition for quality NC platform targets.
North Carolina at a Glance
Key Markets in North Carolina
Charlotte-Concord-Gastonia MSA
The #2 US banking and finance hub and largest NC metro (~2.37M population), anchored by Bank of America, Truist, Wells Fargo East Coast HQ, Honeywell, Nucor, Lowe's, and Duke Energy. Home to the densest cluster of LMM PE firms in the Southeast — Ridgemont ($11B+ AUM), Pamlico Capital, Falfurrias ($1.35B), Summit Park, Plexus Capital, and Frontier Growth — plus active investment banks. Charlotte's PE ecosystem traces back to Bank of America-Wachovia-First Union spinouts, giving the city uniquely deep M&A muscle for a non-coastal market.
Raleigh-Durham-Chapel Hill (Research Triangle)
The fourth-largest US life-sciences market (JLL) with 700+ life-science companies employing 64,500+ and population growth of 10.2% from 2020-2024. Heavy strategic inbound activity from Biogen, Novartis, Novo Nordisk, GSK, Eli Lilly, Fujifilm, and Amgen, with active CDMO and CRO consolidation led by IQVIA, Labcorp, and KBI Biopharma. RTP sponsors QHP Capital (healthcare), Hatteras Venture Partners, NovaQuest Capital, and Pappas Capital anchor the life-sciences PE ecosystem alongside technology-focused Jurassic Capital.
Greensboro-Winston-Salem-High Point (Piedmont Triad)
Legacy furniture and textiles hub at the I-40/I-85 crossroads being reshaped into an advanced manufacturing and logistics corridor. Boeing FedEx Mid-Atlantic hub, Honda Aircraft, Textron, and JetZero's $4.7B factory commitment have transformed deal flow. Toyota's $13.9B Liberty battery plant started production November 2025. The High Point furniture market remains the world's largest home furnishings trade show. The Triad concentrates the state's manufacturing M&A pipeline, with FILOT-equivalent incentive structures driving investment.
Asheville MSA
Tourism and hospitality hub, the craft beverage capital of the Southeast (Sierra Nevada East, New Belgium, Oskar Blues), and a growing healthcare cluster anchored by Mission Health/HCA. Post-Hurricane Helene (late 2024) recovery spending in 2025 drove distressed-asset acquisitions and construction-services consolidation. Asheville's micro-monopoly dynamic — natural geographic barriers limiting competition — drives premium multiples for quality operators in hospitality, healthcare, and specialty food and beverage.
How Does North Carolina Compare?
North Carolina M&A benchmarks vs. neighboring states.
North Carolina Deal Landscape 2025-2026
North Carolina mirrored the national rebound-then-cooling pattern: North American M&A volume rose ~6.9% YoY in Q1 2025 before slowing in Q2 on tariff volatility. GF Data shows PE TEV/EBITDA holding at ~7.2x YTD 2025, though deals above $100M climbed to 10.0x (vs. 8.5x in 2024). PE dominates NC deal flow — Charlotte's big three (Ridgemont, Pamlico, Falfurrias) collectively raised over $7B in new capital in 2025, creating intense competition for quality NC platform targets. The biggest driver is generational ownership transition combined with sponsor-to-sponsor exits from aged portfolios, amplified by NC's booming population drawing out-of-state strategics. The 2.25% corporate tax phasing to 0% by 2030 creates a unique structural tailwind: every year closer to zero widens the economic gap between staying and selling, compressing the exit timeline for C-corp owners.
Charlotte PE Goliaths Scaling with $7B+ in 2025 Fundraising
Three Charlotte-born platforms rooted in Bank of America/Wachovia history all raised record funds: Ridgemont Fund V at $3.975B (exceeding its $2.75B target by ~45%, AUM now $11B+), Pamlico Capital Fund VI at $1.75B, and Falfurrias at $1.35B. Falfurrias deployed $557M into 9 new companies in 2024 including Jumo Health, MOXFIVE, and Snak King, and exited Sauer Brands (Duke's Mayo) to Advent International. This capital overhang is driving intense competition for NC platform targets, pushing multiples 0.3-0.7 turns above national averages.
Insurance & Annuity Take-Privates Hitting Charlotte
Aquarian Capital (RedBird and Mubadala-backed) agreed to acquire Charlotte's Brighthouse Financial for $4.1B ($70/share) in November 2025, among the largest US insurance take-privates of the year. Patient Square Capital simultaneously acquired Charlotte-based Premier, Inc. for approximately $2.6B ($28.25/share, ~23.8% premium), closing late November 2025. These transactions have set benchmark multiples for insurance and financial services platforms across the Carolinas and placed Charlotte firmly on the national large-cap M&A map.
Mega-Industrial Inbound Creating Supplier M&A Tailwind
JetZero's $4.7B Greensboro factory (14,560 jobs), Honda Aircraft's $55.7M HondaJet 2600 expansion, GE Aerospace's $101M NC investment, and Amazon's $10B NC data center plan are seeding aerospace and tech-infrastructure supplier consolidation. Toyota's Liberty battery plant starting production November 2025 adds EV supply-chain M&A. Combined, these investments are fueling LMM roll-ups in MEP/HVAC, precision manufacturing, and specialty trades — exemplified by AAR's $78M HAECO Americas acquisition and Platinum Equity's buyout of Huntersville-based PlayPower from Littlejohn.
RTP Biotech Capex Wave Driving CDMO & CRO Consolidation
RTP captured record life-science capex in 2025: Biogen's $2B manufacturing expansion, Fujifilm Diosynth's $3.2B Holly Springs facility, Amgen $1B, Novo Nordisk $4.1B in Johnston County, and J&J's second $2B Wilson County facility. This investment wave is creating intense demand for contract development and manufacturing organizations, clinical research organizations, and specialized lab-services providers — with PE platforms paying 9-12x EBITDA for quality CDMO assets anchored by FDA-clean inspection histories and recurring blue-chip pharma customers.
Exit Preparation Timeline
A practical roadmap for North Carolina business owners planning an exit.
- Confirm S-corp vs. LLC vs. C-corp in light of Taxed PTE eligibility under G.S. 105-154.1(a) — LLCs taxed as partnerships and S-corps both qualify — and model franchise tax optimization through excess capital distributions, intercompany debt, and holding-company qualification to capture the $500 cap on the first $1M under G.S. 105-122.
- Document federal §41/§174 R&D positions and legacy Article 3J credits with NOL inventory (15-year NC carryforward post-2022); catalog IRC conformity adjustments vs. NC's January 1, 2023 fixed-date conformity date (bonus depreciation add-back, §174 capitalization, §163(j)).
- Evaluate C-corp conversion to capture post-OBBBA QSBS tiered exclusions (50%/75%/100% at 3/4/5-year holds, $75M gross-asset threshold, $15M per-issuer cap under §1202) — NC conforms to §1202 so federally excluded gain flows through to zero NC taxable income; model the 5-year clock start date carefully.
- Initiate JDIG grant compliance review with EDPNC/NC Commerce and preserve any remaining Article 3J legacy credits (20-year tail); engage a sell-side accounting advisor for Quality-of-Earnings readiness, including franchise tax, PTE deduction, and NC income tax normalization in adjusted EBITDA.
- Run quantitative Taxed PTE modeling comparing 2025 (4.25%) vs. 2026 (3.99%) election outcomes coordinated with resident/nonresident owner mix; remember NCDOR Directive TA-23-1 voids late elections — the election must be made on a timely-filed Form D-403 (partnerships) or CD-401S (S-corps) by the 15th day of the 4th month after year-end plus extensions.
- Confirm single-sales-factor apportionment documentation and P.L. 86-272 protections; address NCDOR "doing business" posture under 17 NCAC 5C .0102 and remediate multi-state sales/use tax nexus exposure via NCDOR Voluntary Disclosure Agreements to cap look-back period and waive penalties.
- Initiate NCDOR sales-use successor-liability clearance under G.S. 105-164.38 — the process typically runs 60-90+ days and should be treated as a parallel track, not a closing task; fund a sales/use escrow in asset deals as gap insurance.
- For biotech/life sciences targets, coordinate FDA Establishment Registrations (including BIMO inspection history), DEA registrations, NC Board of Pharmacy wholesaler permits, NC Dept. of Agriculture biologics permits, and engage NCBiotech for letter-of-good-standing prior to buyer outreach.
- Engage Ad Astra and launch a competitive process leveraging Charlotte's PE ecosystem (Ridgemont, Pamlico, Falfurrias, Carousel, Summit Park) and RTP life-sciences buyer universe; target 45-60 buyers, execute NDAs, distribute CIM, and schedule management presentations — competitive tension from Charlotte PE routinely delivers 18-28% premiums over initial indications.
- Confirm the Taxed PTE election on a timely-filed Form D-403 or CD-401S; clean Secretary of State good-standing and resolve any G.S. 105-230 suspensions (forfeiture of right to transact business in NC for failure to file annual report — cure requires reinstatement fee and back filings).
- Inventory NC regulatory license transfers: for healthcare, map each service line to NC CON status under DHHS Division of Health Service Regulation (§131E-176 et seq.) and assess whether change-of-ownership triggers CON notice or new application — structure stock sale where possible to preserve existing approvals; for ABC-licensed targets, plan for location-specific non-transferable permits requiring new applications.
- File NCDOR Voluntary Disclosure Agreements to cap look-back and waive penalties on pre-existing exposure; model the $1-per-$500 real estate excise tax ("revenue stamp") under G.S. 105-228.30 paid by the transferor, plus the G.S. 105-122 franchise tax for the stub year — remember franchise tax is paid in advance, requiring careful withdrawal timing to avoid duplicate-year liability.
- Obtain the NCDOR G.S. 105-164.38 successor-liability clearance certificate and fund a sales/use escrow in asset deals — without this certificate, buyer faces personal liability for seller's unpaid sales/use tax up to the purchase price; deliver to buyer at or before signing.
- File the short-year CD-405 (C-corp) or CD-401S (S-corp) or D-403 (partnership) through date of dissolution with the NC Secretary of State; remember franchise tax is paid in advance — carefully time withdrawal to avoid triggering liability for an additional full year under G.S. 105-122.
- Remit $1-per-$500 revenue stamps (real estate excise tax) at each county Register of Deeds; confirm JDIG grant carryforward eligibility with EDPNC and execute any required grant-succession agreements with NC Commerce to preserve incentive value post-close.
- File the final D-403/CD-401S reporting Taxed PTE allocation with updated NC K-1s reflecting the G.S. 105-153.5(c3) owner deduction; for nonresident sellers, comply with withholding obligations on NC-source income; deliver seller tax affidavit and R&W insurance binder in lieu of large indemnity escrow — the preferred NC market standard for quality LMM deals.
Why North Carolina Business Owners Choose Ad Astra
Local market knowledge and national buyer networks — the combination that drives premium outcomes for North Carolina business owners.
Schedule a ConsultationRTP and Charlotte Market Knowledge
Deep local relationships across the Research Triangle (Raleigh-Durham-Chapel Hill) life-sciences corridor and the Charlotte financial and industrial buyer community, with fluency in the Greensboro/Piedmont Triad advanced-manufacturing base. Ad Astra maintains active dialogue with life-sciences strategics headquartered or heavily invested in RTP — Biogen, Fujifilm Diosynth, KBI Biopharma, IQVIA, Thermo Fisher/Patheon — and Southeast-focused PE platforms, enabling targeted buyer universe construction rather than generic national outreach.
Franchise Tax & Taxed PTE Expertise
Specialized modeling of the G.S. 105-122 franchise tax (including the 2025 $500 cap on the first $1M of base, $1.50/$1,000 thereafter), the 2.25% to 0% corporate income tax phase-out trajectory, and the G.S. 105-154.1/105-131.1A Taxed PTE election mechanics — areas where out-of-state advisors routinely miss value or trigger invalid elections under NCDOR Directive TA-23-1. Pre-close capital distributions and holding-company qualification can preserve the franchise-tax cap, recovering 6-7 figures otherwise lost to diligence surprises.
NC Biotech & Middle-Market PE Network
Active relationships with Charlotte's top-tier PE firms — Ridgemont ($11B+ AUM), Pamlico Capital, Falfurrias, Carousel Capital, Frontier Growth, and Plexus Capital — plus Raleigh-Durham sponsors Hatteras Venture Partners, NovaQuest Capital, Pappas Capital, and Tiverton ($2B AUM). For life-sciences deals, Ad Astra coordinates early engagement with NCBiotech for letter-of-good-standing and EDPNC/NC Commerce for JDIG grant succession, shortening confirmatory diligence by an estimated 3-4 weeks.
NC Regulatory Fluency
Direct working relationships with NCDOR on VDAs, franchise tax audits, and G.S. 105-164.38 sales-tax clearances; the NC Biotechnology Center on loan/grant standstill and assignment; the NC Secretary of State on dissolution/withdrawal timing and good-standing reinstatement under G.S. 105-230; and EDPNC/NC Commerce on JDIG grant succession. For healthcare targets, Ad Astra navigates NC's Certificate of Need regime — among the most stringent nationally — where CON contests routinely extend deal timelines by 12-36 months if not proactively structured.
North Carolina M&A Activity Highlights
Aquarian Capital's $4.1B take-private of Brighthouse Financial (November 2025) at $70/share; transaction closed with stockholder approval in February 2026, retaining Brighthouse's Ballantyne HQ and 1,400-employee footprint in Charlotte.
Ridgemont Equity Partners Fund V closed at $3.975B in 2025, exceeding its $2.75B target by ~45%, with 40 Ridgemont employees personally committing nearly $250M — AUM now exceeds $11B.
JetZero selected Greensboro for a $4.7B factory creating 14,560 jobs in June 2025 — the largest economic development commitment in NC history, with up to $450M in state infrastructure support.
Cold Spring Brewing (Brynwood Partners VIII) acquired Carolina Beverage Group (Mooresville, NC) from SunTx on January 13, 2025; combined entity operates 650,000+ sq ft across MN/NC/TX.
Biogen announced a $2B RTP manufacturing expansion in July 2025 alongside Hatteras Venture Partners' $200M raise (split $177M Fund VII / $30M Opportunity Fund) — Hatteras's largest haul in its 25-year history.
Tax & Deal Structure in North Carolina
North Carolina has one of the most seller-friendly M&A tax environments in the Southeast, combining a low flat individual income tax (4.25% in 2025, 3.99% in 2026) with the scheduled elimination of the corporate income tax (2.25% in 2025 phasing to 0% by 2030 under S.L. 2021-180). The state conforms to federal QSBS §1202, so federally excluded gain flows through to zero NC taxable income. No state estate or inheritance tax (repealed 2013). The unique complication: NC retains a franchise tax on apportioned net worth under G.S. 105-122 that survives the corporate tax phase-out and reshapes stock-deal structuring. Pre-close franchise tax planning through excess capital distributions and holding-company qualification is a recurring value-capture opportunity worth 6-7 figures on quality deals.
Individual Income Tax
FavorableFlat 4.25% in 2025, dropping to 3.99% in 2026 under Session Law 2023-134 (HB 259), with a trigger-based cut to 3.49% possible in 2027. Capital gains are taxed as ordinary income at the same flat rate — no preferential capital gains treatment. On a $40M gain, the state tax drag is approximately $1.7M at 4.25% absent PTE planning. The scheduled 2026 reduction creates a modest incentive to defer close into 2026 where economically feasible.
Corporate Income Tax Phase-Out
FavorableCorporate income tax of 2.25% in 2025 (lowest among the 44 states levying a CIT), declining to 2.0% (2026), 1.0% (2028), and 0% (2030) under G.S. 105-130.3 as amended by S.L. 2021-180 (HB 334). This trajectory materially compresses the economic gap between asset and stock deal structures over time, creates a structural tailwind for buyer IRRs, and makes NC-domiciled C-corps increasingly competitive for PE platform holds.
Taxed Pass-Through Entity Election
FavorableNC offers Taxed PTE elections under G.S. 105-154.1 (partnerships/LLCs, Form D-403) and G.S. 105-131.1A (S-corps, Form CD-401S), allowing entity-level payment at the 4.25% rate to bypass the federal SALT cap. The election is annual and irrevocable after the filing deadline per NCDOR Directive TA-23-1 — late elections are void. For a deal generating $2-3M of NC-source income, a valid PTET election converts state tax into a federally deductible expense, saving seven figures in federal tax.
Franchise Tax on Net Worth
NeutralThe NC franchise tax under G.S. 105-122 is $1.50 per $1,000 of apportioned net worth, with a $500 maximum on the first $1M of base for C-corps, $200 minimum, and $150,000 overall general-base cap (effective 2025 per S.L. 2024-1, S508). This tax survives the corporate income tax phase-out to 0% in 2030. Because it is computed on GAAP net worth apportioned by single-sales-factor, stock sales can materially change the combined group's net-worth base via push-down accounting — pre-close franchise tax cleanup through excess capital distributions and holding-company qualification is a recurring buyer-negotiation point.
QSBS §1202 Conformity
FavorableNC conforms to federal taxable income under G.S. 105-153.5 (individual) and G.S. 105-130.5 (corporate), so federally excluded §1202 gain flows through as excluded from NC taxable income. NC is a fixed-date conformity state (current IRC conformity date January 1, 2023), which predates the July 4, 2025 OBBBA enhancements (tiered 50%/75%/100% at 3/4/5 years, $75M gross-asset threshold, $15M per-issuer cap). Pre-OBBBA QSBS (5-year hold under pre-2025 rules) is fully conformed; post-OBBBA treatment for 2025-2026 dispositions requires confirmation pending General Assembly update of the conformity date.
Real Estate Excise & Successor Liability
NeutralNC imposes a real estate excise tax ("revenue stamp") of $1 per $500 ($2 per $1,000) under G.S. 105-228.30 paid by the transferor; seven coastal counties (Dare, Currituck, etc.) levy additional local transfer tax. No bulk-sales statute, but successor liability for unpaid sales/use tax survives under G.S. 105-164.38 — buyers are personally liable for seller's unpaid tax without a NCDOR clearance certificate. The clearance process runs 60-90+ days and must be initiated well before closing to avoid deal disruption.
Representative Transaction
Illustrative model only. Not representative of a current or past Ad Astra Equity client engagement. Details modified to protect client confidentiality. Ranges are representative.
The Business
Founder-led CDMO / life-sciences contract manufacturer, Research Triangle Park / Durham NC
Key Metrics
Revenue
$35M-$55M TTMEBITDA
$7M-$12M (20-23% margin)Margin
65%+ commercial gross margin; 85-92% customer retentionRetention
>90% provider retention; 12-20 active GMP programsThe Challenge
The scientific founder (CSO) held the majority of tacit process know-how and IP relationships across Duke, UNC, and NC State university license back-chains, requiring a 2-3 year post-close employment and structured tech-transfer protocol. NC biotech regulatory complexity included FDA Establishment Registration and Drug Master File coordination, dual-use/ITAR review on select bioprocess equipment, and NC Biotechnology Center outstanding loan/grant obligations that required standstill and assignment pre-close. The franchise tax under G.S. 105-122 surfaced legacy net-worth positions during diligence that would have triggered incremental tax absent pre-close cleanup.
The Process
- 1Pre-close franchise tax cleanup: excess capital distribution and holding-company qualification preserved the $500 G.S. 105-122 cap on the first $1M of net worth, avoiding a purchase-price adjustment and recovering six figures for the seller.
- 2Taxed PTE election executed on a timely-filed Form D-403 per NCDOR Directive TA-23-1, converting $1.5-$2.0M of state tax on deal gain into a federally deductible entity-level expense — a seven-figure federal tax saving that required precise election timing.
- 3Buyer universe of 45-60 targeted buyers (mid-cap strategic CDMOs, PE platforms with life-sciences theses, Asian and European strategics seeking US footprint post-tariff reshoring); 15-20 executed CDAs, 8-12 IOIs, 6-9 RTP site visits including GMP suite walkthroughs.
- 4Early RTP ecosystem engagement — NCBiotech, EDPNC, Duke and UNC tech-transfer offices — front-loaded IP chain-of-title and JDIG carryforward eligibility, shortening confirmatory diligence by an estimated 3-4 weeks.
- 5NCDOR G.S. 105-164.38 successor-liability clearance certificate obtained in parallel with SPA negotiation; R&W insurance bound in lieu of large indemnity escrow.
Deal Outcome
Enterprise Value
10.0x-13.5x EBITDA
Premium vs. Market
18-28% above initial IOI weighted average
Time to Close
~9-11 months
Seller Rollover
80-85% cash at close, 15-25% rollover equity into PE buyer's platform
Key Lessons
- NC franchise tax pre-close cleanup matters — diligence surfacing legacy net-worth positions created a purchase-price adjustment risk that a pre-close capital distribution and holding-company qualification eliminated entirely, preserving the G.S. 105-122 $500 cap.
- Taxed PTE timing under NCDOR Directive TA-23-1 delivered seven-figure federal savings by converting state tax on deal gain into a deductible entity-level expense — the election window is narrow and irrevocable; missing it is the most expensive avoidable mistake in NC M&A.
- Early RTP ecosystem engagement (NCBiotech, EDPNC, Duke and UNC tech-transfer offices) front-loaded IP chain-of-title, JDIG carryforward eligibility, and FDA registration continuity, shortening confirmatory diligence by 3-4 weeks and directly improving close probability.
- Competitive processes involving both strategic CDMOs and PE platforms consistently deliver 18-28% premiums over initial inbound indications — the Charlotte and RTP buyer ecosystems are deep enough that a well-run auction creates genuine tension even for niche technical targets.
Frequently Asked Questions
Common questions about selling a business in North Carolina.
Still have questions? Let's talkAlso serving neighboring states
Ready to Explore Your North Carolina Exit?
Schedule a confidential conversation to discuss your North Carolina business, your goals, and how our local expertise and national buyer network can maximize your outcome.